Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis
- Creators
- Palandri, Francesca
- Palumbo, Giuseppe Alberto
- Bonifacio, Massimiliano
- Tiribelli, Mario
- Benevolo, Giulia
- Martino, Bruno
- Abruzzese, Elisabetta
- D'Adda, Mariella
- Polverelli, Nicola
- Bergamaschi, Micaela
- Tieghi, Alessia
- Cavazzini, Francesco
- Ibatici, Adalberto
- Crugnola, Monica
- Bosi, Costanza
- Latagliata, Roberto
- Di Veroli, Ambra
- Scaffidi, Luigi
- DE MARCHI, FEDERICO
- Cerqui, Elisa
- Anaclerico, Barbara
- De Matteis, Giovanna
- Spinsanti, Marco
- Sabattini, Elena
- Catani, Lucia
- Aversa, Franco
- Di Raimondo, Francesco
- Vitolo, Umberto
- Lemoli, Roberto Massimo
- Fanin, Renato
- Merli, Francesco
- Russo, Domenico
- CUNEO, ANTONIO
- Reggiani, Maria Letizia Bacchi
- Cavo, Michele
- Vianelli, Nicola
- Breccia, Massimo
- Others:
- Palandri, Francesca
- Palumbo, Giuseppe Alberto
- Bonifacio, Massimiliano
- Tiribelli, Mario
- Benevolo, Giulia
- Martino, Bruno
- Abruzzese, Elisabetta
- D'Adda, Mariella
- Polverelli, Nicola
- Bergamaschi, Micaela
- Tieghi, Alessia
- Cavazzini, Francesco
- Ibatici, Adalberto
- Crugnola, Monica
- Bosi, Costanza
- Latagliata, Roberto
- Di Veroli, Ambra
- Scaffidi, Luigi
- DE MARCHI, Federico
- Cerqui, Elisa
- Anaclerico, Barbara
- De Matteis, Giovanna
- Spinsanti, Marco
- Sabattini, Elena
- Catani, Lucia
- Aversa, Franco
- Di Raimondo, Francesco
- Vitolo, Umberto
- Lemoli, Roberto Massimo
- Fanin, Renato
- Merli, Francesco
- Russo, Domenico
- Cuneo, Antonio
- Reggiani, Maria Letizia Bacchi
- Cavo, Michele
- Vianelli, Nicola
- Breccia, Massimo
Description
In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count < 200x109/l (p=0.028), and a time-interval between MF diagnosis and RUX start > 2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (> 20) Total Symptom Score significantly correlated with lower probability of response (p < 0.001). Increased disease severity, a delay in RUX start and titrated doses < 10 mg BID were associated with patients achievinglower response rates. An early treatment and higher RUX doses may achieve better therapeutic results.
Additional details
- URL
- http://hdl.handle.net/11567/885995
- URN
- urn:oai:iris.unige.it:11567/885995
- Origin repository
- UNIGE